Research
Hormonal
In the absence of adipose tissue, the liver becomes the primary site of action for thiazolidinediones (TZDs) like rosiglitazone.
For patients with severe lipoatrophy, TZDs like rosiglitazone work by acting on the liver, not fat. If you lack fat tissue, the liver is the key to the drug's effectiveness. In normal individuals, the liver's role in this drug's action is minor compared to fat tissue.
GoodQualifiesHIGH confidence
Inactivation of AZIP liver PPAR-gamma also abolished the hypoglycemic and hypolipidemic effects of rosiglitazone, demonstrating that, in the absence of adipose tissue, the liver is a primary and major site of thiazolidinedione action.
Why this rating
Clear demonstration of drug efficacy loss when the target tissue is removed.
Source
Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass
Oksana Gavrilova et al. · Journal of Biological Chemistry · 2003
DOI 10.1074/jbc.m300043200
mechanism_onlyCited 765×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Liver PPAR-gamma is essential for triglyceride clearance; its absence causes hyperlipidemia and insulin resistance even when hepatic steatosis is reduced.Good
- Liver PPAR-gamma protects extra-hepatic tissues from triglyceride accumulation and insulin resistance by facilitating hepatic lipid clearance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →